Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Tianxing Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-0150-1343; OpenAlex author ID A5112877053. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 4 papers · 2024: 3 papers · 2025: 7 papers · 2026: 8 papers

Papers 24

  1. Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance. Co-author DOI 10.1002/advs.202507346↗
  2. CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. Co-author DOI 10.1038/s41467-026-75132-3↗
  3. Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy. Co-author DOI 10.1038/s42003-026-09770-0↗
  4. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  5. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Co-author DOI 10.1136/gutjnl-2025-336277↗
  6. Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps. Last author DOI 10.1158/0008-5472.can-26-0151↗
  7. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-0323↗
  8. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  9. Targeting Mast Cell Activation and MIF-Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer. Co-author DOI 10.1002/advs.202509930↗
  10. The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217408↗
  11. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2025.102292↗
  12. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Co-author DOI 10.1038/s41422-025-01098-4↗
  13. Adaptation to cystine limitation stress confers a targetable lipid metabolism vulnerability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-025-68099-0↗
  14. Hypoxic and Acidic Tumor Microenvironment-Driven AVL9 Promotes Chemoresistance of Pancreatic Ductal Adenocarcinoma via the AVL9-IκBα-SKP1 Complex. Co-author DOI 10.1053/j.gastro.2024.10.042↗
  15. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  16. KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. Co-author DOI 10.1007/s00018-024-05442-6↗
  17. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. First author DOI 10.1053/j.gastro.2024.02.046↗
  18. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  19. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective… Co-author DOI 10.1097/js9.0000000000000425↗
  20. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Co-author DOI 10.1136/gutjnl-2022-327492↗
  21. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  22. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2022.0569↗
  23. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Co-author DOI 10.1136/gutjnl-2020-321952↗
  24. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20180749↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 22 shared papers, 2019–2026 · strength 4.14
  2. Yongjie Xie · 17 shared papers, 2022–2026 · strength 3.15
  3. Xiuchao Wang · 14 shared papers, 2019–2026 · strength 2.42
  4. Tiansuo Zhao · 13 shared papers, 2019–2026 · strength 2.17
  5. Chongbiao Huang · 12 shared papers, 2019–2026 · strength 1.95
  6. Jing Liu · 10 shared papers, 2019–2026 · strength 1.60
  7. Shengyu Yang · 9 shared papers, 2019–2026 · strength 1.43
  8. Yukuan Feng · 6 shared papers, 2025–2026 · strength 1.31
  9. Wenna Jiang · 8 shared papers, 2019–2026 · strength 1.24
  10. Song Gao · 8 shared papers, 2019–2026 · strength 1.23
  11. Jun Yu · 5 shared papers, 2024–2026 · strength 1.00
  12. Chao Yang · 4 shared papers, 2025–2026 · strength 0.87
  13. Qingxiao Fang · 4 shared papers, 2025–2026 · strength 0.86
  14. Shangheng Shi · 4 shared papers, 2026 · strength 0.86
  15. Yifei Wang · 3 shared papers, 2026 · strength 0.67
  16. Chuntao Gao · 3 shared papers, 2023–2026 · strength 0.60
  17. Bo Ni · 3 shared papers, 2024–2025 · strength 0.53
  18. Yiping Zou · 3 shared papers, 2023–2025 · strength 0.51
  19. Rui Liu · 2 shared papers, 2026 · strength 0.45
  20. Liangliang Wu · 2 shared papers, 2025–2026 · strength 0.43
  21. Yunzhan Li · 2 shared papers, 2025–2026 · strength 0.41
  22. Chao Xu · 2 shared papers, 2025–2026 · strength 0.41
  23. Xiaofan Guo · 2 shared papers, 2023–2026 · strength 0.37
  24. Kaiyuan Wang · 2 shared papers, 2025 · strength 0.37
  25. Song Gao · 2 shared papers, 2025–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.